Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing SIOUX FALLS, S.D., Nov. 21, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical
SIOUX FALLS, S.D., Nov. 15, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy SIOUX FALLS, S.D., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), ("SAB”), a clinical-stage biopharmaceutical company with a
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease SIOUX FALLS, S.D., Nov. 03, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), ("SAB”), a
SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses SIOUX FALLS, S.D., Sept. 28, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy
SIOUX FALLS, S.D., Sept. 23, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), ("SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors,
SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.
Expects cash is sufficient to fund operations for the forward twelve months SIOUX FALLS, S.D., Aug. 10, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted,
SIOUX FALLS, S.D., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics ( Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors,
